Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: The ARPEGGIO trial

Diabetes Care

Volumn 33, Issue 3, 2010, Pages 605-607

  Hollander, Priscilla A ^a   Amod, Aslam ^b   Litwak, León E ^c   Chaudhari, Umesh ^d  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Chatsmed Garden Hospital   (South Africa)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; TRIACYLGLYCEROL;

ADULT; ANXIETY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HORMONE ANTAGONISTS; HUMANS; INSULIN; MIDDLE AGED; OBESITY; PIPERIDINES; PLACEBOS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; YOUNG ADULT;

EID: 77649260031     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-0455     Document Type: Article

References (14)

1. International Diabetes Federation. Clinical Guidelines Task Force: global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-593
2. American Diabetes Association. Standards of medical care in diabetes, 2007. Diabetes Care 2007;30(Suppl. 1):S4-S41
3. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice 2007;13(Suppl. 1):3-68
4. Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-1041
5. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27:73-100
6. Després JP, Van Gaal L, Golay A, Rissanen A. Rimonabant improves oral glucose tolerance in non-diabetic overweight/obese patients with/without comorbidities. 67th Scientific Sessions of the American Diabetes Association, 22-26 June 2007, Chicago, IL [abstract no. 345-OR]
7. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIONorth America: a randomized controlled trial. JAMA 2006;295:761-775
8. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006;368:1660-1672
9. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-1397
10. Van Gaal LF, Scheen AJ, Rissanen AM, Rössner S, Hanotin C, Ziegler O, the RIOEurope Study Group. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: 2-year results from the RIO-Europe Study. EHJ 2008; 29:1761-1771
11. Rosenstock J, Hollander P, Chevalier S, Iranmanesh A, the SERENADE Study Group. The SERENADE Trial: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight and lipid profile in drug-naïve type 2 diabetes. Diabetes Care 2008;31:2169-2176
12. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006;29:2137-2139
13. Herling AW, Kilp S, Elvert R, Haschke G, Kramer W. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rat. Endocrinology 2008;149:2557-2566
14. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a metaanalysis of randomized trials. Lancet 2007;370:1706-1713